



November 27, 2020

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-3525-4707

**Kyorin Pharmaceutical Receives Marketing Approval for injectable
New Quinolone Antibacterial Agent “Lasvic® Intravenous Drip Infusion Kit 150mg”**

TOKYO, Japan (November 27, 2020) —Kyorin Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Shigeru Ogihara), a wholly owned subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of November 27, 2020 to market the injectable new quinolone antibacterial drug Lasvic® Intravenous Drip Infusion Kit 150mg (“the Injection”).

Through a domestic phase 3 clinical study in a double-blind comparative study for community-acquired pneumonia and an open-label, uncontrolled study for secondary infection of chronic respiratory disease and lung abscess, the effectiveness and safety of the Injection were evaluated and approved.

Kyorin Pharmaceutical Co., Ltd. has promoted its activities to provide solutions in the field of infectious diseases under the medium-term business plan "HOPE100-Stage 3-". By adding the Injection to its product lineup in the respiratory tract infections, and by providing up-to-date information continuously, Kyorin Pharmaceutical Co.,Ltd. aims to further contribute to the proper use of antibacterial agents and the treatment of patients. This contribution will also lead to the efforts against antimicrobial resistance (AMR) which has become a problem recently.

Further details, including the timing of release and projected sales, will be announced in a timely manner after the Injection has been listed on the National Health Insurance drug price list.

(Product Information)

Brand name : Lasvic® Intravenous Drip Infusion Kit 150mg
Generic name : Lascufloxacin Hydrochloride
INN : LSFX

Indications:

<Bacterial strains> The genus *Staphylococcus*, the genus *Streptococcus*, *Streptococcus pneumoniae*, the genus *Enterococcus*, *Moraxella (Branhamella) catarrhalis*, *Escherichia coli*, the genus *Klebsiella*, the genus *Enterobacter*, *Haemophilus influenzae*, *Legionella pneumophila*, the genus *Peptostreptococcus*, the genus *Veillonella*, the genus *Bacteroides*, the genus *Prevotella*, the genus *Porphyromonas*, the genus *Fusobacterium* and *Mycoplasma pneumoniae* that are sensitive to this drug

<Diseases> Pneumonia, lung abscess, secondary infection of chronic respiratory disease

Dosage and Administration:

The usual dosage for adults is 300 mg of lascufloxacin on the first day of administration and 150 mg once daily on the second and subsequent days of administration.